8Ross R. Atherosclerosis - an inflammatory disease [ J ]. N Engl J Med, 1999,340 (2) :115 -126.
9Jialal I, Devaraj S, Inflammation and atherosclerosis: the value of the high - sensitivity C - reactive protein assay as a risk marker[ J]. Am J Clin Pathol, 2001, 116 (Suppl) : 108 - 115.
10Sasaki R, Yamano S, Yamamoto, et al. Vascular remodeling of the carotid artery in patients with untreated essential hypertension increases with age[J]. Hypertens Res, 2002,25:373 -379.
4Ridker PM.High-sensitivity C-reactive protein and cardiovascular risk:rationale for screening and primary prevention.Am J Cardiol,2003,92(4B):17-22.
5Lehrke M,Millington SC,Lefterova M,et al.CXCL16 Is a Marker of Inflammation,Atherosclerosis,and Acute Coronary Syndromes in Humans.J Am Coil Cardiol,2007,49:442-449.
6Wilbanks A,Zondlo SC,Murphy K,et al.xpression cloning of the STRL33/ BONZO/TYMSTR ligand reveals elements of CC,CXC,and CX3C chemokines.J Immunol,2001,166(8):5145-5154.
7Camilla Smith,Bente Halvorsen,et al.High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease:down-regulatory effects of statins.Cardiovascular Research,2008,79(1):195-203.
8Van Gelder IC,Crijns HJ,Tieleman RG,et al.Chronic atrial fibrilla-tion.Success of serial cardioversion therapy and safety of oral anticoag-ulation[J].Arch Intern Med,2006,156(22):2585-2592.
9Ridker PM.High-sensitivity C-reactive protein:potential adjunct forglobal risk assessment in the primary prevention of cardiovascular dis-ease[J].Circulation,2007,103(13):1813-1818.
10Ewy GA,Ulfers L,Hager WD,et al.Response of atrial fibrillation totherapy:role of etiology and left atrial diameter[J].J Electrocardiol,2008,13(4):119-123.
